Comirnaty (COVID-19 Vaccine, mRNA) mRNA COVID-19 vaccine (2025-2026 formulation targeting the LP.8.1 variant) For active immunization to prevent COVID-19 caused by SARS-CoV-2 in adults aged 65 years ...
The Comirnaty 2025-2026 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, a descendant of JN.1. The Food and Drug Administration (FDA) has approved Comirnaty ® (LP.8.1-adapted monovalent ...
NEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe ...
The Food and Drug Administration has approved Novavax's Nuvaxovid 2025-2026 formula for the prevention of COVID-19 in adults 65 years and older or individuals 12 years through 64 years of age with at ...
The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®. The new vaccine is indicated for active immunization to prevent COVID-19 caused by SARS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results